Autologous Tumor Cell Vaccine Genetically Modified To Express GM-CSF and Block Expression of TGFβ2

被引：0
|
作者：
Maples, Phillip B. [1 ]
Kumar, Padmasini [1 ]
Yu, Yang [1 ]
Oxendine, Ila [1 ]
Kuhn, Joseph [2 ]
Nemunaitis, John [1 ,3 ,4 ,5 ]
机构：
[1] Gradalis Inc, Dallas, TX USA
[2] Gen & Oncol Surg Associates, Dallas, TX USA
[3] Mary Crowley Canc Res Ctr, Dallas, TX USA
[4] Baylor Sammons Canc Ctr, Dallas, TX USA
[5] Texas Oncol PA, Dallas, TX USA
来源：
MOLECULAR THERAPY | 2009年 / 17卷
关键词：
D O I：
暂无
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
引用
收藏
页码：S212 / S212
页数：1
相关论文
共 50 条
  • [1] Phase I Trial of TGF-β2 Antisense GM-CSF Gene-Modified Autologous Tumor Cell (TAG) Vaccine
    Olivares, Jairo
    Kumar, Padmasini
    Yu, Yang
    Maples, Phillip B.
    Senzer, Neil
    Bedell, Cynthia
    Barve, Minal
    Tong, Alex
    Pappen, Beena O.
    Kuhn, Joseph
    Magee, Mitchell
    Wallraven, Gladice
    Nemunaitis, John
    CLINICAL CANCER RESEARCH, 2011, 17 (01) : 183 - 192
  • [2] Immune response and survival of refractory cancer patients who received TGF-β2 antisense/GM-CSF gene modified autologous tumor cell (TAG) vaccine
    J Nemunaitis
    N Senzer
    J Olivares
    P Kumar
    M Barve
    J Kuhn
    T Nemunaitis
    M Magee
    Y Yu
    G Wallraven
    B O Pappen
    P B Maples
    Gene Therapy, 2013, 20 : 875 - 879
  • [3] Immune response and survival of refractory cancer patients who received TGF-β2 antisense/GM-CSF gene modified autologous tumor cell (TAG) vaccine
    Nemunaitis, J.
    Senzer, N.
    Olivares, J.
    Kumar, P.
    Barve, M.
    Kuhn, J.
    Nemunaitis, T.
    Magee, M.
    Yu, Y.
    Wallraven, G.
    Pappen, B. O.
    Maples, P. B.
    GENE THERAPY, 2013, 20 (09) : 875 - 879
  • [4] Therapy of established tumor with a novel tumor vaccine developed by fusion of tumor cells with GM-CSF genetically modified dendritic cells
    Hirofumi Hamada
    实验血液学杂志, 1997, (03) : 309 - 310
  • [5] Recombinant GM-CSF plus autologous tumor cells as a vaccine for patients with mesothelioma
    Powell, A
    Creaney, J
    Broornfield, S
    Van Bruggen, I
    Robinson, B
    LUNG CANCER, 2006, 52 (02) : 189 - 197
  • [6] Comparative antitumor effect among GM-CSF, IL-12 and GM-CSF + IL-12 genetically modified tumor cell vaccines
    Miguel, A.
    Herrero, M. J.
    Sendra, L.
    Botella, R.
    Algas, R.
    Sanchez, M.
    Alino, S. F.
    CANCER GENE THERAPY, 2013, 20 (10) : 576 - 581
  • [7] Genetically engineered herpes simplex viruses that express IL-12 or GM-CSF as vaccine candidates
    Parker, JN
    Pfister, LA
    Quenelle, D
    Gillespie, GY
    Markert, JM
    Kern, ER
    Whitley, RJ
    VACCINE, 2006, 24 (10) : 1644 - 1652
  • [8] Correlation of Immune Response with Long Term Survival of Refractory Cancer Patients Who Received TGF-β2 Antisense/GM-CSF Gene Modified Autologous Tumor Cell (TAG) Vaccine
    Nemunaitis, John
    Senzer, Neil
    Olivares, Jairo
    Kumar, Padmasini
    Barve, Minal
    Kuhn, Joseph
    Nemunaitis, Thomas
    Magee, Mitchell
    Yu, Yang
    Wallraven, Gladice
    Pappen, Beena O.
    Maples, Phillip B.
    MOLECULAR THERAPY, 2012, 20 : S180 - S180
  • [9] Comparative antitumor effect among GM-CSF, IL-12 and GM-CSF+IL-12 genetically modified tumor cell vaccines
    A Miguel
    M J Herrero
    L Sendra
    R Botella
    R Algás
    M Sánchez
    S F Aliño
    Cancer Gene Therapy, 2013, 20 : 576 - 581
  • [10] Silencing of Foxp3 enhances the antitumor efficacy of GM-CSF genetically modified tumor cell vaccine against B16 melanoma
    Miguel, Antonio
    Sendra, Luis
    Noe, Veronica
    Ciudad, Carles J.
    Dasi, Francisco
    Hervas, David
    Jose Herrero, Maria
    Alino, Salvador F.
    ONCOTARGETS AND THERAPY, 2017, 10 : 503 - 514
12345